Chronic infection and metabolic stress: a converging axis driving hypertension and MASLD outcomes

Clicks: 3
ID: 318106
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #57 of 62 articles by views in American Journal of Hypertension

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly recognized as a systemic cardiometabolic disorder arising from the convergence of metabolic stress, chronic low-grade (smoldering) inflammation, and vascular pathology. MASLD extends beyond hepatic fat accumulation, and is tightly linked to arterial hypertension and cardiovascular disease, with arterial hypertension acting as a disease modifier that accelerates fibrosis progression and deteriorates long-term outcomes. Emerging evidence suggests that chronic infections, particularly Helicobacter pylori infection, may further amplify this cardiometabolic continuum by sustaining inflammatory signaling, oxidative stress, insulin resistance, and endothelial damage. These mechanisms substantially overlap with crucial pathogenic pathways implicated in MASLD progression and hypertension onset. At the molecular level, AMP-activated protein kinase (AMPK) signaling represents a key integrative axis linking energy homeostasis, inflammation, and blood pressure regulation. Pharmacological AMPK activation, exemplified by imeglimin targeting presenilin enhancer-2, highlights the translational potential of therapies addressing hepatic and vascular injury simultaneously. This perspective summarizes clinical and mechanistic evidence supporting an integrated, systems-based framework in which chronic infection and metabolic stress converge along a shared axis to drive hypertension and MASLD. It underscores the need to incorporate metabolic regulation, cardiovascular risk modification, and selected infectious determinants into future risk stratification models and therapeutic strategies.
Reference Key
openalex_W7165547940 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jannis Kountouras, Stergios A Polyzos, Elisabeth Vardaka, Christos Zavos, Michael Doulberis
Journal American Journal of Hypertension
Year 2026
DOI
10.1093/ajh/hpag064
URL
https://doi.org/10.1093/ajh/hpag064
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.